Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting
Altavant Sciences Provides Update on Clinical Plan for PAH Candidate, Rodatristat Ethyl, at Upcoming American Thoracic Society Annual Meeting News provided by Share this article Share this article CARY, N.C. and BASEL, Switzerland, May 10, 2021 /PRNewswire/ -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory diseases, will be providing an update on the clinical development of rodatristat ethyl, the company's lead candidate for the treatment of pulmonary arterial hypertension (PAH), at the annual meeting of the Ameri...
Source: prnewswire.com